Amanda Starc

[Becker Friedman Institute for Economics @BeckerFriedman]

New working paper, "Painful Bargaining: Evidence from Anesthesia Rollups," from @asil_aslihan, Paulo Ramos, @amandastarc1, and Thomas Wollmann (@ChicagoBooth). https://t.co/0hUCnNREoe

[Amanda Starc @AmandaStarc1]

@Jabaluck @RyanReedHill (I hate James Joyce)

[Amanda Starc @AmandaStarc1]

@ashdgandhi @florianederer @asil_aslihan (Standard errors w TWFE are available in the appendix :)

[Craig Garthwaite @C_Garthwaite]

The @KelloggSchool Deep Dive into Healthcare is our premier educational event to train the next generation of business decision makers in healthcare.

This amazing film pulls back the curtain on these immersive weekends ...

https://t.co/wNw0k8FhQl

[Brad Shapiro @btshapir]

If you live in Chicago and you're mourning the fact that your POTUS vote doesn't matter, please still vote. We have a highly consequential school board election happening.

[Peter Hull @instrumenthull]

Reminder: MA star ratings do not seem to correlate *at all* with the health effects of MA plans

https://t.co/7QCVHxbIYN

[Kellogg School @KelloggSchool]

What will we pay for the next groundbreaking drug?

Kellogg's Amanda Starc and @C_Garthwaite explore the trade-off at the heart of pharmaceutical innovation in episode 4 of the Insight Unpacked podcast, season two. #KelloggLeader https://t.co/3vAV1IKyKc

[Kellogg School @KelloggSchool]

There's a new season of Insight Unpacked—the series where Kellogg faculty break down a complex business topic. And boy does it have one for you this season: American healthcare and its web of misaligned incentives. Subscribe and listen now. #KelloggLeader https://t.co/ufvpVOIllq

[Dan Diamond @ddiamond]

There’s no bigger health care company than UnitedHealth Group. It’s grown to be the nation’s largest insurer — and largest employer of physicians. It’s bigger than Google and Microsoft.

Now some lawmakers want to chop it down.

https://t.co/2v69j4KSvq

[Kellogg School @KelloggSchool]

Prof. Amanda Starc explains why the American prescription-drug market can be so complicated to get our arms around—even for the experts. #KelloggLeader https://t.co/uLulwwdYQb

[Peter Hull @instrumenthull]

I struggled with depression and anxiety throughout grad school. There are days I still do today.

Seeking, or even considering getting help is not a sign of weakness. It's a sign of strength.

You are not alone.

https://t.co/9f5YSexWGN

[Aspen Economic Strategy Group @AspenEcon]

Rising pharmaceutical drug prices have spurred heated debate about a process that can be complex & opaque. In their paper for the AESG’s 2023 policy volume, @C_Garthwaite & @AmandaStarc1 @KelloggSchool take a look at how drug prices are set & offer a series of reforms to improve market competition and efficiency.
https://t.co/KmJEalRMCr

[Aspen Economic Strategy Group @AspenEcon]

The complex process of pharmaceutical drug pricing has contributed to rising drug costs in the US. Figure 11 from @C_Garthwaite & @AmandaStarc1’s paper, “Why Drug Pricing Reform is Complicated,” shows the large out-of-pocket costs that Medicare enrollees can face today.
https://t.co/KmJEalRMCr

[Aspen Economic Strategy Group @AspenEcon]

In a new @EconoFactOrg memo, AESG authors @C_Garthwaite & @AmandaStarc1 break down provisions in the IRA that allow Medicare to negotiate certain drug prices & discuss how these changes could impact firms’ incentives to invest in future innovations.
https://t.co/otdW50ED8O

[Aspen Economic Strategy Group @AspenEcon]

In Ch. 3, @C_Garthwaite & @AmandaStarc1 describe the complex process of pharmaceutical price setting in the US & propose reforms to make the market more competitive and efficient. https://t.co/UZq7n6QtzK

[Keith Marzilli Ericson (he/him/his) @ProfKMEricson]

Part B: higher launch prices, lower price growth. Net effect is still to raise prices compared to commercial payment.

Joint work with @angieacquatella and @AmandaStarc1

[Craig Garthwaite @C_Garthwaite]

This is a new paper with Amanda Starc.

In it we provide a number of policy suggestions for pharma market.

Perhaps more important, the first 2/3 of paper is a “primer” on how drugs are bought and distributed in the United States.

There is a particular focus on the economics.

[Neil Irwin @Neil_Irwin]

I found this paper from @AspenEcon really useful for grappling with the issues and tradeoffs around prescription drug pricing.

https://t.co/QgHqSoCKTj

[Aspen Economic Strategy Group @AspenEcon]

Read Garthwaite & Starc's complete primer on pharmaceutical drug pricing in the US and their proposed policy solutions to improve the US drug pricing system here: https://t.co/UZq7n6QtzK

[Peter Hull @instrumenthull]

Important findings, consistent with our 2021 QJE on the variation in mortality effects of Medicare Advantage plans (totally uncorrelated with star ratings!)
https://t.co/4RD6j5N5mM